Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Research breakthrough could halt melanoma metastasis

15.11.2012
In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin.

More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form. With further research, the approach used by the scientists could lead to targeted therapies that stop metastasis in melanoma and potentially a broad range of additional cancers.

The study published online in the journal Cancer Research was led by Paul B. Fisher, M.Ph., Ph.D., Thelma Newmeyer Corman Endowed Chair in Cancer Research and program co-leader of Cancer Molecular Genetics at Virginia Commonwealth University Massey Cancer Center, chairman of VCU's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine. Fisher and his colleagues found that Raf kinase inhibitor protein (RKIP) interacted with and suppressed mda-9/syntenin. Mda-9/syntenin was originally cloned in Fisher's laboratory, and was shown in previous studies to interact with another protein, c-Src, to start a series of chemical reactions that lead to increased metastasis.

"Prior research suggests that RKIP plays a seminal role in inhibiting cancer metastasis, but, until now, the mechanisms underlying this activity were not clear," says Fisher. "In addition to providing a new target for future therapies, there is potential for using these two genes as biomarkers for monitoring melanoma development and progression."

Through their experiments, the scientists discovered that RKIP physically binds with mda-9/syntenin, and this physical interaction inhibits mda-9/syntenin expression. This finding opens the possibility of developing small molecules that mimic RKIP to be used as drugs to treat metastasis in melanoma and other cancers.

Additionally, the team found that levels of mda-9/syntenin were higher than levels of RKIP in malignant and metastatic melanoma cells while levels of RKIP were higher than levels of mda-9/syntenin in healthy melanocytes, which are the cells that produce pigment in the skin, eyes and hair. The inverse relationship between the two proteins suggests that changes in their levels of expression could be used as a diagnostic tool, enabling clinicians to track the development of the disease or gauge a patient's response to treatments.

"Our findings represent a major breakthrough in understanding the genetic mechanisms that lead to metastasis in melanoma. Prior studies have shown that levels of mda-9/syntenin are elevated in a majority of cancers, including melanoma, suggesting that our findings could be applicable for a wide range of diseases," says Fisher.

Now that the researchers have demonstrated the ability of RKIP to inhibit mda-9/syntenin-mediated metastasis, they are focusing their attention on developing small molecules imitating RKIP that could be used as new treatments for melanoma.

Fisher collaborated on this study with Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at VCU Massey Cancer Center, Blick Scholar and assistant professor in the Department of Human and Molecular Genetics at VCU School of Medicine and member of the VCU Institute of Molecular Medicine; Swadesh K. Das, Ph.D., instructor in the Department of Human and Molecular Genetics at VCU School of Medicine and VCU Institute of Molecular Medicine; Sujit K. Bhutia, Ph.D., Upneet K. Sokhi, Ph.D. graduate student, Belal Azab, Ph.D., and Zhao-zhong Su, Ph.D., all from the Department of Human and Molecular Genetics at VCU School of Medicine; Talha Anwar, Ph.D., Erika L. Moen, Ph.D., and Devasis Chatterjee, Ph.D., all from the Department of Medicine at Rhode Island Hospital; and Maurizio Pellecchia, Ph.D., from the Sanford-Burnham Medical Research Institute in La Jolla, CA.

Funding for this study was supported in part by National Institutes of Health grants 1R01 CA097318, P01 CA104177 and P20 RR17695; the National Foundation for Cancer Research; the Goldhirsh Foundation for Brain Tumor Research; the Dana Foundation; the American Cancer Society; and the Samuel Waxman Cancer Research Foundation.

The full manuscript of this study is available online at: http://cancerres.aacrjournals.org/content/early/2012/10/11/0008-5472.CAN-12-0402.abstract?sid=6fae281f-1cec-4331-b5bd-6019f04ac54b

News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.

About VCU Massey Cancer Center

VCU Massey Cancer Center is one of only 67 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 877-4-MASSEY for more information.

About VCU and the VCU Medical Center

Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.

John Wallace | EurekAlert!
Further information:
http://www.vcu.edu

More articles from Life Sciences:

nachricht Why do animals fight members of other species?
24.04.2015 | University of California - Los Angeles

nachricht Is a small artificially composed virus fragment the key to a Chikungunya vaccine?
24.04.2015 | Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Elektromobilität: Ultraleichtes Kraftpaket für das elektrische Fliegen

Siemens hat einen einzigartigen Elektromotor entwickelt, der hohe Leistung mit einem minimalen Gewicht kombiniert. Durch konsequente Optimierung aller Komponenten stellt der neue Antrieb in seiner Klasse einen Weltrekord beim Leistungsgewicht auf. Dadurch kommt der routinemäßige Einsatz von elektrisch angetriebenen Flugzeugen oder Helikoptern einen großen Schritt näher.

Manchmal lässt sich eine technische Revolution ganz knapp in einer einzigen Zahl zusammenfassen. In diesem Fall lautet sie: fünf Kilowatt pro Kilogramm – das...

Im Focus: Fast and Accurate 3-D Imaging Technique to Track Optically-Trapped Particles

KAIST researchers published an article on the development of a novel technique to precisely track the 3-D positions of optically-trapped particles having complicated geometry in high speed in the April 2015 issue of Optica.

Daejeon, Republic of Korea, April 23, 2015--Optical tweezers have been used as an invaluable tool for exerting micro-scale force on microscopic particles and...

Im Focus: Von Innen nach Außen: Rätsel der galaktischen Scheiben gelöst

Ein Team von Astronomen unter der Leitung von Ivan Minchev, Wissenschaftler am Leibniz-Institut für Astrophysik Potsdam (AIP), hat mithilfe hochmoderner theoretischer Modelle das Rätsel um die Entwicklung der Galaxienscheiben gelöst. Die jetzt veröffentlichte Studie zeigt, dass sich Sternpopulationen gleichen Alters durch Galaxienkollisionen nach außen hin ausweiten. Ähnlich wie die Blüten einer Rose reichern sich diese Populationen schichtweise in der Galaxie an und formen so allmählich die dicke Scheibe.

„Wir können nun zum ersten Mal zeigen, dass dicke Scheiben nicht nur aus alten Sterngenerationen bestehen, sondern – in einem größeren Abstand zum...

Im Focus: NOAA, Tulane identify second possible specimen of 'pocket shark' ever found

Pocket sharks are among the world's rarest finds

A very small and rare species of shark is swimming its way through scientific literature. But don't worry, the chances of this inches-long vertebrate biting...

Im Focus: Morbus Crohn: neuer Entstehungsmechanismus entschlüsselt

Bakteriengemeinschaften verursachen Darmentzündung

Morbus Crohn zählt zu den chronisch-entzündlichen Darmerkrankungen (CED). Bei der Krankheit spielt die genetische Veranlagung eine Rolle - und offenbar auch...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Internationale Familienunternehmensforschung

24.04.2015 | Veranstaltungen

Internationaler Tag der Immunologie am 29. April 2015

24.04.2015 | Veranstaltungen

Wirtschaftsempfang 2015: WissensRÄUME

24.04.2015 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Simulation und virtuelle Welten: Virtueller Messerundgang mit dem Smartphone

24.04.2015 | Informationstechnologie

Elektromobilität: Ultraleichtes Kraftpaket für das elektrische Fliegen

24.04.2015 | Energie und Elektrotechnik

Siemens integriert Sitop-Stromversorgung in Prozessleitsystem Simatic PCS 7

24.04.2015 | Messenachrichten